Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.2134
-0.0104 (-4.65%)
Mar 27, 2026, 10:38 AM EDT - Market open
Theriva Biologics Employees
As of December 31, 2025, Theriva Biologics had 16 total employees, including 15 full-time and 1 part-time employees. The number of employees decreased by 6 or -27.27% compared to the previous year.
Employees
16
Change (1Y)
-6
Growth (1Y)
-27.27%
Revenue / Employee
n/a
Profits / Employee
-$1,578,063
Market Cap
9.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | -6 | -27.27% | 15 | 1 |
| Dec 31, 2024 | 22 | 0 | - | 20 | 2 |
| Dec 31, 2023 | 22 | 1 | 4.76% | 22 | 0 |
| Dec 31, 2022 | 21 | 5 | 31.25% | 21 | 0 |
| Dec 31, 2021 | 16 | 6 | 60.00% | 16 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| CollPlant Biotechnologies | 57 |
| CytoMed Therapeutics | 43 |
| Curis | 34 |
| Lunai Bioworks | 29 |
| BioLineRx | 28 |
| Imunon | 25 |
| CalciMedica | 16 |
TOVX News
- 3 months ago - Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) - GlobeNewsWire
- 5 months ago - Theriva Biologics Provides Response to Unusual Market Action - GlobeNewsWire
- 5 months ago - Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds - GlobeNewsWire
- 6 months ago - Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) - GlobeNewsWire
- 8 months ago - Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results - GlobeNewsWire
- 11 months ago - Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - GlobeNewsWire
- 11 months ago - Theriva Biologics Announces Closing of $7.5 Million Public Offering - GlobeNewsWire
- 11 months ago - Theriva Biologics Announces Pricing of $7.5 Million Public Offering - GlobeNewsWire